Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUMC-BOB1-B7-TCR.1 in relapsed or refractory B-cell malignancies
NL-OMON59083Phase 2Recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Jun 2026
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of LUMC-BOB1-B7-TCR.1 in B cell acute lymphoblastic leukemia (B-ALL), multiple myeloma (MM) and B-cell non-Hodgkin lymphoma (B-NHL), sponsored by Leiden University Medical Center. Primary endpoints: Manufacturing feasibility, Treatment feasibility and 5 more. Started Jun 2026; status: recruiting.
02
Drugs
LUMC-BOB1-B7-TCR.1
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)multiple myeloma (MM)B-cell non-Hodgkin lymphoma (B-NHL)
Beyond the preview
Go deeper on NL-OMON59083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59083.